The STAREE-HEART sub-study will examine the effect of statin treatment over a 3-year period compared with placebo on markers of cardiac ageing (myocardial dysfunction). This will include determining global longitudinal strain with transthoracic echocardiography, atrial fibrillation with home measures twice daily for two weeks and changes in biomarkers.
STAREE-HEART is an ancillary study nested in the Statins in Reducing Events in the Elderly (STAREE) double-blind randomised placebo-controlled trial. STAREE is investigating whether statins can prolong good health and maintain independence amongst older people and is enrolling men and women 70 years of age and over who are free from cardiovascular disease, diabetes and dementia. STAREE-HEART will recruit a subset of STAREE participants before they are randomised to STAREE study drug. STAREE-HEART will involve an additional suite of cardiac assessments in these participants and will provide detailed information about the clinical effect of statins on myocardial function.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
369
Ultrasound of heart
Single lead ECG screening twice daily for two weeks
12-lead ECG screening
Monash University; School of Public Health and Preventative Medicine: STAREE trial
Melbourne, Victoria, Australia
Curtin University
Perth, Western Australia, Australia
Global longitudinal strain (GLS) measured via transthoracic echocardiography.
Change in global longitudinal strain.
Time frame: 3 years
Atrial fibrillation (AF) measured via single lead handheld ECG recordings.
Development of new AF.
Time frame: 3 years
Wavelet analysis via 12-lead ECG with Energy Waveform displays.
Increases detection of Heart Failure (HF).
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.